Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,875.55
    -1.50 (-0.02%)
     
  • Bitcoin USD

    64,708.33
    +1,195.28 (+1.88%)
     
  • CMC Crypto 200

    1,369.18
    +56.55 (+4.51%)
     
  • S&P 500

    5,004.22
    -6.90 (-0.14%)
     
  • Dow

    37,977.20
    +201.82 (+0.53%)
     
  • Nasdaq

    15,488.15
    -113.35 (-0.73%)
     
  • Gold

    2,405.00
    +7.00 (+0.29%)
     
  • Crude Oil

    83.13
    +0.40 (+0.48%)
     
  • 10-Yr Bond

    4.6230
    -0.0240 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

International Markets Could Drive Spinraza Sales in 2017

Despite robust demand trends in the US, launches in new countries are expected to drive revenue growth of Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza in 4Q17.